SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Clinical Criteria Revision for Hereditary Angioedema Agents (HAE) effective June 1,2023
Date: June 9, 2023
Attention: All Providers
Effective Date: June 1, 2023
Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective June 1, 2023, the Texas Health and Human Services (HHSC) added age and diagnosis restriction for HAE agents. Please see the drugs impacted below:
Drug
Procedure Code
Age
Diagnosis
Berinert®
J0597
≥ 5 years
D84.1
Kalbitor®
J1290
≥ 12 years
D84.1
Firazyr®
J1744
≥ 18 years
D84.1
Takhzyro®
J0593
≥ 2 years
D84.1
How this impacts providers: Starting June 1 2023, TCHP will have diagnosis and age restrictions for HAE agents including Berinert®, Kalbitor®, Firazyr® and Takhzyro®. Providers will have to adhere to the age and diagnosis restriction in order to get reimbursed.
Next steps for providers: Prescribers should share this communication with their staff. Providers must stay up-to-date on the latest restrictions and indications for these agents to ensure appropriate use and maximize patient outcomes. Provider must submit documentation (such as office chart notes, lab results, other pertinent clinical information, etc.) supporting that the member has met all appropriate criteria for medication approval. Updated prior authorization (PA) forms can be found on Navitus. Since these drugs also qualify for the medical benefit, please refer to the Outpatient Drug Services Handbook Chapter of the Texas Medicaid Provider Procedure Manual for more details on the clinical policy and prior authorization requirements.
Note: If request is for a dose or indication that is not approved by the U.S. Food and Drug Administration (FDA), medical rational must be submitted in support of therapy (such as high-quality peer reviewed literature, acceptable compendia or evidence based practice guidelines) and exceptions will be considered on a case-by-case basis.
